Johnson & Johnson (JNJ)


NYSE - NYSE Real Time Price. Currency in USD
119.41+0.19 (+0.16%)
As of 2:38 PM EDT. Market open.
People also watch:
PGMRKKOPFEXOM
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open119.05
Prev Close119.22
Bid119.44 x 400
Ask119.45 x 200
Day's Range118.81 - 119.52
52wk Range91.76 - 126.07
1y Target EstN/A
Market Cap326.69B
P/E Ratio (ttm)22.25
Beta0.70
Volume2,579,454
Avg Vol (3m)6,432,098
Dividend & Yield3.20 (2.72%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • 3 Stocks With Better Dividends Than Procter & Gamble
    Motley Fool18 minutes ago

    3 Stocks With Better Dividends Than Procter & Gamble

    Income investors don't have to settle for weak dividend growth and soft sales gains.

  • TheStreet.com1 hour ago

    Heartening News for J&J: Americans Feel 'Great' About the Economy

    As consumer confidence and health care spending soar, Johnson & Johnson is becoming one of the best total return packages available.

  • American City Business Journals2 hours ago

    FDA approves Horsham biotech firm’s drug for Crohn’s disease

    The Food and Drug Administration approved expanding the label for Horsham-based Janssen Biotech’s Stelara product to include its use for the treating Crohn's disease. Crohn’s disease is a chronic inflammatory condition of the gastrointestinal tract that affects about 700,000 Americans. The FDA approval of Stelara specified its use in adults 18 or older with moderately to severely active Crohn’s disease who have failed, or were intolerant to, treatment with immunomodulators or corticosteroids, but who never failed treatment with a tumor necrosis factor blocker.